West Virginia University Logo

Disease Site: Lung

18 protocol(s) meet the specified criteria

  • 59R5-003A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Platinum Therapy in Subjects with Untreated Extensive Stage Small Cell Lung Cancer
  • A081105Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) ALCHEMIST
  • A151216Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  • ABI-007-NSCL-0003A Phase III,Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate NAB-Paclitaxel(Abraxane) As Maintenance Treatment After Induction With NAB-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)
  • COG-AOST1321Phase 2 Study of Denosumab, a RANK Liggand Antibody, for Recurrent or Refractory Osteosarcoma
  • COG-AOST1421A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
  • D4190C00006A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer
  • D6020C00001A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination with MEDI4736 in Subjects with Advanced Malignancies
  • E4512A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fushion Protein
  • GO29431A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (Anti−PDL1 ANTIBODY) COMPARED WITH CISPLATIN OR CARBOPLATIN+PEMETREXED FOR PD-L1−SELECTED CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON−SMALL CELL LUNG CANCER
  • GO29432A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer
  • GO29436A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naive Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer
  • GO29437A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Carboplatin + Paclitaxel or MPDL3280A in Combination with Carboplatin + Nab- Paclitaxel versus Carboplatin + Nab-Paclitaxel in Chemotherapy Naïve Patients with Stage IV Squamous Non−Small Cell Lung Cancer
  • LOXO-TRK-15002A Phase II Basket Study of Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
  • NRG-CC003Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
  • PRE0504A Phase I/II Study of Glembatumumab Vedotin in Patients with gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung
  • S1400Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.
  • X396-CLI-101X-396-CLI-101 Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer